Full Text View
Tabular View
No Study Results Posted
Related Studies
Open-Label Study of Oral Treprostinil in Digital Ulcers (DISTOL-EXT)
This study is not yet open for participant recruitment.
Verified by United Therapeutics, February 2009
First Received: February 16, 2009   Last Updated: February 19, 2009   History of Changes
Sponsored by: United Therapeutics
Information provided by: United Therapeutics
ClinicalTrials.gov Identifier: NCT00848107
  Purpose

This open label extension trial will allow ongoing treatment of subjects who participated in the randomized controlled trials, and will provide long term information about the safety of treprostinil diethanolamine SR in this patient population


Condition Intervention
Systemic Sclerosis
Drug: treprostinil diethanolamine

Study Type: Interventional
Study Design: Treatment, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study
Official Title: Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine: An Open-Label Multicenter Extension Study

Resource links provided by NLM:


Further study details as provided by United Therapeutics:

Primary Outcome Measures:
  • adverse events and laboratory parameters [ Time Frame: every 3-6 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • digital ulcers [ Time Frame: every 3-6 months ] [ Designated as safety issue: No ]
  • patient function and QOL [ Time Frame: every 3-6 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 150
Study Start Date: August 2009
Intervention Details:
    Drug: treprostinil diethanolamine
    sustained release tablet; BID dosing; up to 16 mg BID
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Eligible subjects who completed assessments for the final visit of the previous controlled trials and who signed appropriate informed consent are eligible to enroll in this extension study.
  • If a female of childbearing potential, the subject must agree to continue practicing an acceptable method of birth control (i.e., surgical sterilization, approved hormonal contraceptives, barrier methods [such as a condom or diaphragm] used with a spermicide, or an intrauterine device).

Exclusion Criteria:

  • Have had any change in clinical status that, in the opinion of the Investigator, would pose a safety risk for participation in this extension study;
  • Have been found to be unable to complete study assessments in the previous controlled trial;
  • Have prematurely discontinued study drug during the previous study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00848107

Contacts
Contact: Kristan Rollins, PharmD 919-425-8167 krollins@unither.com

  Show 26 Study Locations
Sponsors and Collaborators
United Therapeutics
Investigators
Principal Investigator: James Seibold, MD University of Michigan Scleroderma Program
  More Information

No publications provided

Responsible Party: United Therapeutics ( Kristan Rollins, PharmD )
Study ID Numbers: TDE-DU-202
Study First Received: February 16, 2009
Last Updated: February 19, 2009
ClinicalTrials.gov Identifier: NCT00848107     History of Changes
Health Authority: United States: Food and Drug Administration;   United Kingdom: Research Ethics Committee;   United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by United Therapeutics:
systemic sclerosis
scleroderma
digital ulcers
vasculopathy

Study placed in the following topic categories:
Skin Diseases
Ulcer
Treprostinil
Connective Tissue Diseases
Scleroderma
Scleroderma, Diffuse
Sclerosis
Scleroderma, Systemic
Cardiovascular Agents
Ischemia
Antihypertensive Agents

Additional relevant MeSH terms:
Pathologic Processes
Skin Diseases
Therapeutic Uses
Treprostinil
Connective Tissue Diseases
Scleroderma, Diffuse
Sclerosis
Scleroderma, Systemic
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 30, 2009